In the highly regulated world of pharmaceuticals, where precise communication is paramount and language barriers can impede progress, the evolution of machine translation stands as a modern beacon of innovation and efficiency. From its nascent stages to the sophisticated systems we employ today, machine translation has become an indispensable efficiency generating tool.
The trajectory of machine translation evolution and speed of recent adoption mirrors the rapid advancements in the development of artificial intelligence (AI). Early iterations relied on rudimentary rule-based or statistical algorithms, often yielding translations that fell way short of industry standards for accuracy and precision. The arrival of neural machine translation (NMT) changed the landscape. NMT models, powered by deep learning across vast datasets of pharmaceutical libraries, have the capacity to comprehend context and intricate language specific nuances. Adding further AI technologies, such as Large Language Models (LLM) and Generative AI (Gen AI), results in a paradigm shift in machine driven quality translation, opening the doors of possibility for language service providers.
So, what happens next? What are the current limitations of machine translation and how far can we really take it?
They say to ‘err is human’, but the same can sometimes be said for machines. While machine learning has made significant strides in recent years it can still produce inconsistent precision. AI hallucinations, where machines generate erroneous or misleading text, can lead to grammatically incorrect sentences or text that deviates from the required output. Also, attention disparity, where rare or seemingly lower resourced language pairs receive less extensive investment, can result in significant output variances or suboptimal translation quality in comparison to more nurtured language pairs.
As a result, while machines can support the automation of the translation process to a significant extent, humans must play an indispensable role in creating the required accuracy by directing and correcting the nuances of language that machines may overlook.
The integration of human expertise and machine capabilities yields exponential efficiencies in the translation process. This tactical combination is already producing transformative outcomes today and promises to meet the rigorous quality requirements of the pharmaceutical and medical device industries in the future, while addressing demands for both time and cost efficiency. The future possibilities represent an exciting frontier and one of the most compelling aspects in the ongoing evolution of machine translation.
Is it time for our imaginations to be near-term reality?
Is it possible to imagine a time, in which researchers, clinicians, and regulatory authorities from around the globe can exchange information, share findings, and navigate complex regulatory frameworks without the burden of language barriers? Will it be possible for author communities to generate core documents in the framework of their own native language, whilst seamlessly and effortlessly producing alternative language versions in real time, enabling flawless information comprehension?
These AI visions could one day be reality thanks to the continuous advancements in AI and machine learning algorithms. As AI technologies continue to emerge, change, and develop we must understand and implement technologies such as reinforcement learning, which uses algorithms that adapt and refine translations based on feedback from domain experts, into our processes and methodologies. The right combination of supervised, semi-supervised and unsupervised learning will provide the pharmaceutical industry with translation and language service technologies that will be brimming with the potential to reduce language barriers to a minimum. In fact, the capacity for machine translation to revolutionize communication within the pharmaceutical sector is almost limitless.
At ICON we believe in providing proven progressive solutions. We empower our pharmaceutical partners to accelerate the pace of drug and medical devices development using a tried and tested infrastructure that fully meets all requirements with no risk. Our Language Services solutions and AI Center of Excellence enable us to transcend linguistic barriers and unlock new frontiers without boundaries whilst understanding the unique needs and challenges of our clients.
Contact us to learn more about ICON Language Services. Together we can unlock new possibilities, break down barriers, and shape the future of healthcare.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel